- Home
- S vs NUVL Comparison
S vs NUVL Comparison
Compare S & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- S
- NUVL
- Stock Information
- Founded
- S 2013
- NUVL 2017
- Country
- S United States
- NUVL United States
- Employees
- S N/A
- NUVL 200
- Industry
- S EDP Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- S Technology
- NUVL Health Care
- Exchange
- S Nasdaq
- NUVL Nasdaq
- Market Cap
- S 6.0B
- NUVL 6.0B
- IPO Year
- S 2021
- NUVL 2021
- Fundamental
- Price
- S $17.21
- NUVL $83.09
- Analyst Decision
- S Buy
- NUVL Strong Buy
- Analyst Count
- S 28
- NUVL 9
- Target Price
- S $24.11
- NUVL $118.89
- AVG Volume (30 Days)
- S 5.9M
- NUVL 396.7K
- Earning Date
- S 08-28-2025
- NUVL 11-11-2025
- Dividend Yield
- S N/A
- NUVL N/A
- EPS Growth
- S N/A
- NUVL N/A
- EPS
- S N/A
- NUVL N/A
- Revenue
- S $907,381,000.00
- NUVL N/A
- Revenue This Year
- S $24.17
- NUVL N/A
- Revenue Next Year
- S $20.69
- NUVL N/A
- P/E Ratio
- S N/A
- NUVL N/A
- Revenue Growth
- S 25.39
- NUVL N/A
- 52 Week Low
- S $15.36
- NUVL $55.54
- 52 Week High
- S $29.29
- NUVL $106.32
- Technical
- Relative Strength Index (RSI)
- S 42.23
- NUVL 56.32
- Support Level
- S $17.26
- NUVL $81.02
- Resistance Level
- S $18.26
- NUVL $86.34
- Average True Range (ATR)
- S 0.57
- NUVL 3.63
- MACD
- S -0.12
- NUVL 0.28
- Stochastic Oscillator
- S 9.23
- NUVL 66.33
About S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.